Scarica l'app Stockscreener
20.37
4.25%
0.83
Dopo l'orario di chiusura:
20.37
Arcus Biosciences Inc Borsa (RCUS) Ultime notizie
Is Arcus Biosciences (RCUS) Pricing Reflect Its 1‑Year Surge And Mixed Valuation Signals - simplywall.st
Arcus Biosciences Inc (RCUS) Q4 2025 Earnings Call Highlights: S - GuruFocus
Decoding Arcus Biosciences Inc (RCUS): A Strategic SWOT Insight - GuruFocus
Earnings call transcript: Arcus Biosciences beats EPS expectations in Q4 2025 - Investing.com Nigeria
Arcus (RCUS) Q4 2025 Earnings Call Transcript - AOL.com
RCUS: Casdatifan delivers superior efficacy in RCC, driving strong financials and market potential - TradingView
Arcus Biosciences Files For Mixed Shelf - TradingView
RCUS: 2025 net loss widened to $353M on $247M revenue; $1.0B cash supports late-stage pipeline - TradingView
Arcus Biosciences, Inc. SEC 10-K Report - TradingView
Arcus Biosciences Earnings Review: Q4 Summary - Benzinga
Arcus Biosciences Provides Pipeline Update on Its Clinical-Stage Investigational Molecules and Discovery Programs - marketscreener.com
Arcus Biosciences in spotlight: Kidney drug trial results at stake - Investing.com India
Can Arcus Biosciences Inc stock double in the next yearJuly 2025 Decliners & Real-Time Buy Zone Alerts - baoquankhu1.vn
Arcus Biosciences Inc (RCUS) Q4 2025 Earnings Report Preview: Wh - GuruFocus
Arcus Biosciences (NYSE:RCUS) Shares Up 10.1%Here's Why - MarketBeat
Market Catalysts: Is Arcus Biosciences Inc in a long term uptrendJuly 2025 Selloffs & Entry Point Confirmation Signals - baoquankhu1.vn
Arcus Biosciences (RCUS) Showcases Promising Data for Casdatifan in Cancer Study - GuruFocus
Late-line kidney cancer patients top a year without progression on Arcus drug - Stock Titan
Arcus Biosciences’ cancer drug gets orphan drug status - MSN
Investment Report: Can Arcus Biosciences Inc disrupt its industryTreasury Yields & Consistent Growth Stock Picks - baoquankhu1.vn
Is Arcus Biosciences Inc. stock worth buying before Fed actionWeekly Trade Recap & High Conviction Buy Zone Picks - mfd.ru
Here’s what analysts think about Arcus Biosciences (RCUS) - MSN
Aberdeen Group plc Makes New $4.42 Million Investment in Arcus Biosciences, Inc. $RCUS - MarketBeat
Earnings Beat: What’s Arcus Biosciences Inc.’s historical returnTrade Entry Report & Community Supported Trade Ideas - mfd.ru
Arcus Biosciences (RCUS) Stock Analysis: Exploring a 65% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Here's What Analysts Think About Arcus Biosciences (RCUS) - Finviz
Here’s What Analysts Think About Arcus Biosciences (RCUS) - Insider Monkey
A Look At Arcus Biosciences (RCUS) Valuation After Wells Fargo Downgrade And Shifting Analyst Sentiment - Yahoo Finance
How Arcus Biosciences Inc. (RCUS) Affects Rotational Strategy Timing - Stock Traders Daily
What’s Arcus Biosciences Inc.’s historical returnQuarterly Growth Report & Step-by-Step Trade Execution Guides - mfd.ru
Arcus Biosciences Presents First Postive Data for Oral Metastatic Kidney Cancer Treatment - MSN
Arcus Biosciences (NYSE:RCUS) Rating Lowered to "Hold" at Wells Fargo & Company - MarketBeat
How cyclical is Arcus Biosciences Inc.’s revenue streamWeekly Trade Report & High Return Trade Opportunity Guides - mfd.ru
RCUS: Wells Fargo Downgrades Arcus Biosciences, Lowers Price Tar - GuruFocus
This Inspire Medical Systems Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday - Benzinga
What Analysts Are Saying About Arcus Biosciences Stock - Benzinga
Candriam S.C.A. Takes $5.15 Million Position in Arcus Biosciences, Inc. $RCUS - MarketBeat
Cancer drug developer Arcus sets Feb. 25 call on 2025 results - Stock Titan
Is Arcus Biosciences Inc. stock a smart retirement pickQuarterly Investment Review & Safe Capital Investment Plans - mfd.ru
Arcus Advances Quemliclustat With New Phase 1 Study: What Investors Should Know - TipRanks
Arcus Biosciences stock hits 52-week high at $21.03 By Investing.com - Investing.com South Africa
Arcus Biosciences stock hits 52-week high at $21.03 - Investing.com
Arcus Biosciences (NYSE:RCUS) Cut to Sell at Wall Street Zen - MarketBeat
(RCUS) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Wall Street Analysts See a 57.56% Upside in Arcus Biosciences (RCUS): Can the Stock Really Move This High? - sharewise.com
Aug Decliners: How correlated is Arcus Biosciences Inc to the S P500Portfolio Risk Report & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Arcus Biosciences, Inc. (NYSE:RCUS) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Arcus Biosciences, Inc. (RCUS): Analyst Consensus Signals 51% Upside Potential Amid Robust Clinical Pipeline - DirectorsTalk Interviews
What is Arcus Biosciences Inc.’s valuation compared to sectorTrend Reversal & Capital Efficient Trade Techniques - mfd.ru
Arcus Biosciences Grants Stock Options to Employees - intellectia.ai
Arcus Biosciences Announces New Employment Inducement Grants - marketscreener.com
Bear Alert: How does Arcus Biosciences Inc score in quality rankingsJuly 2025 Analyst Calls & Community Consensus Trade Alerts - baoquankhu1.vn
Responsive Playbooks and the RCUS Inflection - Stock Traders Daily
Market Review: Can Arcus Biosciences Inc be recession proofWeekly Risk Summary & Breakout Confirmation Trade Signals - baoquankhu1.vn
Published on: 2026-01-23 23:49:02 - baoquankhu1.vn
Arcus Biosciences (RCUS): Investor Outlook Reveals 43% Upside Potential Amid Biotech Innovations - DirectorsTalk Interviews
1.18%
0.45%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):